P erforin/Granzyme (Gzm) 3 pathway is a key mechanism for cytotoxic lymphocytes to kill intracellular pathogens and tumor cells (1, 2) . Perforin (also known as pore-forming protein) released from cytotoxic granules assists the entry of Gzms into the target cell cytosol (3, 4) . Gzms are a group of serine proteases that initiate target cell apoptosis. They include GzmA, B, C, D, E, F, G, H, K, and M. Nine mouse and five human Gzms have been identified (5) . GzmA and B are the most abundant Gzms in CTLs, and lymphokine-activated killer cells and their functions have been well defined (3, 6) . GzmH, K, and M in humans are called orphan Gzms because their roles are less defined.
The five human Gzms differ in their chromosome locations and substrate specificities. GzmA and K are tryptases that locate on chromosome 5q11-12. GzmB is an aspase locating on 14q11.2. GzmH is a chymase that is colocated with GzmB. GzmM is a metase locating on chromosome 19p13.3 (7, 8) . GzmA induces ssDNA nicks as well as apoptotic morphology and loss of cell membrane integrity (9) . GzmA initiates a caspase-independent death pathway through targeting an endoplasmic reticulum-associated SET complex that contains three GzmA substrates: the nucleosome assembly protein SET, the DNA-bending protein HMG2, and the apurinic endonuclease Ape1 (10, 11) . SET cleavage releases the GzmA-activated DNase (NM23H1) to nick DNA (12) . The execution of apoptosis by GzmB generally occurs by activation of the caspase family of cysteine proteases that triggers caspase cascade (13) . GzmB can directly process several procaspases and some key caspase pathway substrates, such as Bid, inhibitor of caspase-activated DNase (ICAD), DNA-PKcs, NuMa, poly(ADP-ribose) polymerase (PARP), and laminB (3) . GzmB causes a caspase-dependent death pathway with DNA fragmentation. GzmB leads to DNA fragmentation through activation of the caspase-activated DNase (CAD) via degradation of its inhibitor ICAD (14, 15) . CAD exists as a heterodimer with ICAD in a resting cell where CAD is inactive. ICAD is not cleaved in the induction of apoptosis in GzmB-deficient CTLs (16) . The mechanism used by GzmB to initiate DNA fragmentation by inactivating the DNase inhibitor ICAD is reminiscent of the activation of nick-induced nuclease NM23H1 by GzmA cleavage of its inhibitor SET (12) .
GzmM is an orphan Gzm that cleaves preferentially after methionone, leucine, or norleucine (17, 18) . GzmM is constitutively highly expressed in NK cells, whereas it is not expressed in CD4 ϩ or CD8 ϩ T cells either constitutively or after stimulation (19) . One study compared the cytolysis of three NK cell lines and showed that stronger cytotoxicity of NK cell lines is consistent with higher expression of GzmM (20) . It suggests GzmM may play an important role in NK cell-mediated cytolysis for killing virally infected or transformed cells. A recent study reported that GzmM induces a novel form of perforin-dependent death without caspase activation and DNA fragmentation (21) . In this study, we found that GzmM triggers caspase-dependent apoptosis with typical DNA laddering. The DNA fragmentation was confirmed by TUNEL assay. GzmM can directly cleave ICAD to activate CAD, leading to DNA damage. Furthermore, GzmM degrades the DNA damage sensor enzyme PARP to prevent cellular DNA repair and force apoptosis.
Materials and Methods

Cell lines, Abs, and reagents
Jurkat cells were grown in RPMI 1640 medium supplemented with 10% FCS, 50 mM 2-ME, 100 U/ml penicillin, and 100 g/ml streptomycin. HeLa cells were grown in DMEM medium containing 10% FCS, 20 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Commercial Abs were rabbit antisera against caspase 3 (BD Pharmingen) andsheep anti-rabbit IgG (Santa Cruz Biotechnology), and Alexa 488-conjugated donkey anti-mouse IgG (Molecular Probes). Rabbit antiserum against ICAD was provided by Dr. R. P. Sekaly (Laboratoire d'Immunologie, Université de Montreal, Montreal, Canada). Annexin V FITC was from BD Pharmingen, and PI from Sigma-Aldrich. ProLong Antifade kit was from Molecular Probes. In Situ cell death detection kit was from Roche Applied Science.
Production of active and inactive GzmM, rICAD, and rPARP
The cDNA encoding mature human GzmM was PCR amplified from fulllength cDNA of GzmM (RZPD Deutsches Ressourcenzentrum) and subcloned into the yeast expression vector pPICZ␣A (Invitrogen Life Technologies). The sequence of the forward primer containing XhoI site was 5Ј-ACTCTCGAGAAAAGAATCATCGGGGGCCGGGAGGTG-3Ј. The reverse primer containing XbaI site and polyhistidine tag for purification was 5Ј-ATCTCTAGATCAATGATGGTGGTGATGATGGGCCGATC GGCCGGTGACCTTC-3Ј. The resulting construct permitted the sequence of mature human GzmM to immediately follow the Kex2 signal cleavage site of the Saccharomyces cerevisiae ␣-factor secretion signal. The vector was linearized with SacI and transformed into the X33 strain of Pichia pastoris, according to the manufacturer's instruction. Clones with the integrated human GzmM cDNA were selected by resistance to Zeocin (Invitrogen Life Technologies). After 3 days of induction with methanol, the conditioned medium from the shaker flask cultures was isolated and loaded onto the QuiStand benchtop system (Amersham Biosciences) for concentration and buffer exchange. One-step purification was performed using nickel affinity chromatography. The concentration of rGzmM was determined by bicinchoninic acid assay. GzmM catalytic site Ser 182 was mutated to alanine by PCR mutagenesis. The mutated S-AGzmM sequence was subcloned to pPICZ␣A as GzmM and verified by DNA sequencing. Recombinant S-AGzmM was expressed and purified, as above. Full-length cDNA coding human ICAD was provided by Dr. X. Wang (Department of Molecular Biology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX) and was subcloned into pET26b
ϩ . Full-length cDNA of human PARP was subcloned into pET15b. Recombinant human ICAD and PARP were expressed in BL21(DE3) and purified using nickel affinity chromatography.
GzmM loading with PJ
Pro-Ject protein transfection reagent (PJ) kit (Pierce) was prepared and aliquoted, according to the manufacturer's instruction. GzmM or S-AGzmM was diluted in loading buffer (HBSS, 1 mM MgCl 2 , 1 mM CaCl 2 , and 1 mg/ml BSA) and incubated with appropriate volume of PJ at room temperature for 5 min. Target cells were harvested and washed twice with cold HBSS. The indicated number of cells was cultured with PJ/GzmM complex in 50 l of loading buffer at 37°C for 4 h. Cells were pelleted for subsequent assays.
Cytotoxicity assay
Target cells were labeled with 100 Ci of sodium 51 Cr-chromate (Na 2 CrO 4 ) at 37°C for 1 h. After being thoroughly washed, 1 ϫ 10 4 -labeled cells were incubated with 1 M S-AGzmM or GzmM alone or with PJ in the presence or absence of 100 M ZVAD-fmk at 37°C for 4 h. The supernatant from each tube was carefully transferred into a disposable tube. Specific 51 Cr release was counted on the 1450 MicroBeta counter (Pharmacia) and was calculated as follows: percentage of 51 Cr release ϭ ((test release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release)) ϫ 100.
Detection of apoptosis
Jurkat cells were treated with 1 M GzmM or S-AGzmM alone or with PJ at 37°C for 4 h in the presence or absence of 100 M ZVAD-fmk. Jurkat cells cultured with 50 ng/ml staurosporine (STP) for 20 h served as a positive control. Treated cells were double stained with annexin V-Fluos and propidium iodide (PI) before being evaluated by flow cytometry using a FACSCalibur (BD Biosciences). Analysis was performed using CellQuest software (BD Biosciences).
Flow-TUNEL assay with In Situ cell death detection kit (Roche Applied Science) was performed on treated cells, according to the manufacturer's instruction. Briefly, treated cells were washed three times with PBS, fixed with 2% paraformaldehyde in PBS for 1 h at room temperature, and permeabilized with freshly prepared 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. A total of 50 l of TUNEL reaction mixtures was added into each sample and incubated for 1 h at 37°C in a humidified atmosphere in the dark. After washing twice, cells were visualized using immunofluorescent microscopy.
Jurkat cells treated as above were fixed, permeabilized as described, and incubated with 5 g/ml Hoechst 33342 (Sigma-Aldrich) in PBS for 10 min in dark and plated on the slide for observation. Images were captured using a Nikon microscope camera.
Klenow incorporation assay
Klenow fragment of DNA polymerase I (New England Biolabs) was used to label DNA nicks, as described (22) . Briefly, 2 ϫ 10 5 Jurkat cells were buffer treated or treated with 1 M S-AGzmM or GzmM pretreated with NPase lysis buffer for 4 h. Treated cells were incubated with 5 U of Klenow and 10 Ci of [ 32 P]dATP at 37°C for 1 h. Radiolabeled nuclei were washed thoroughly, dotted, and detected with phosphor screen. The radioactivity counts were recorded with Storm program (Pharmacia) and analyzed with ImageQuant software. The values shown were comparative [ 32 P]dATP incorporations and expressed as mean Ϯ SEM. Radiolabeled DNA was also separated on 1% alkaline agarose gel electrophoresis, as described (12) .
DNA fragmentation assay
A total of 5 ϫ 10 5 Jurkat cells lysed with 0.5% Nonidet P-40 buffer was buffer treated or treated with 1 M S-AGzmM and indicated doses of GzmM in 50 l of HBSS supplemented with 1 mM MgCl 2 , 1 mM CaCl 2 , and 1 mg/ml BSA at 37°C for 4 h in the presence or absence of ZVADfmk. Genomic DNA was extracted and analyzed by agarose gel electrophoresis. Briefly, after incubation, 330 l of buffer containing 100 mM Tris-HCl (pH 8.5), 5 mM EDTA, 0.2 M NaCl, 0.2% w/v SDS, and 0.2 mg/ml proteinase K was added to each reaction and incubated at 37°C overnight. NaCl was then added to a final concentration of 1.5 M, and the nuclear debris was spun down for 15 min in a microcentrifuge at room temperature. The DNA in the supernatant was precipitated with an equal volume of 100% ethanol. The DNA precipitate was washed once with 70% (v/v) ethanol and resuspended in 20 l of TE buffer (10 mM Tris⅐HCl (pH 7.4), 1 mM EDTA) supplemented with 200 g/ml DNase-free RNase A at 37°C for 2 h, the DNA was loaded onto a 2% agarose gel with 2 g/ml ethidium bromide, and electrophoresis was conducted at 5 V/cm for 2 h. Genomic DNA of Jurkat cells treated with 1 M GzmM or S-AGzmM alone or with PJ at 37°C for 4 h in the presence or absence of 100 M ZVAD-fmk was also extracted and analyzed by agarose gel electrophoresis.
Laser-scanning confocal microscopy
Jurkat cells were treated with 1 M S-AGzmM or GzmM in the presence or absence of PJ for the indicated times, washed, and plated on polylysinecoated slides. After fixing with 4% paraformaldehyde for 20 min at room temperature and permeabilizing with 0.1% Triton X-100 for another 20 min, the cells were incubated at room temperature for 1 h with 5 g/ml anti-His-tag mAb, 50 g/ml donkey serum, and 100 g/ml RNase I. After washing twice with cold PBS, the cells were stained with Alexa 488-conjugated donkey anti-mouse IgG and soaked for 5 min in PBS containing 0.1 g/ml PI. The slides were mounted with ProLong Antifade reagent and observed using laser-scanning confocal microscopy (Olympus FV500 microscope).
Cleavage assay
Cell lysates were prepared with 0.5% Nonidet P-40 lysis buffer at 4°C for 15 min and centrifuged at 13,000 rpm for 15 min to remove nuclei and cell debris. Cell lysates (equivalent to 2 ϫ 10 5 cells) or 0.5 g of recombinant protein were incubated with indicated doses of GzmM or S-AGzmM for indicated time intervals. For in vivo cleavage assay, cells loaded with GzmM/PJ were lysed with 0.5% Nonidet P-40 lysis buffer. The reactions were terminated in 1ϫ SDS loading buffer before being run on SDS-PAGE gels and immunoblotted with specific Abs, as indicated.
For N-terminal sequencing, the cleaved products of rICAD were run on SDS-PAGE gels and transferred to polyvinylidene difluoride membrane. After staining with Coomassie R-250, the polyvinylidene difluoride band was cut down and analyzed using ABI Procise 492cLC sequencer. The data were analyzed using Model 610 software program supplied by Applied Biosystems.
Results
PJ can directly load GzmM into target cells causing apoptotic nuclear morphological changes
Recombinant human active GzmM and inactive S-AGzmM were expressed in P. pastoris and purified by nickel affinity chromatography. The enzymatic activity of rGzmM was detected by hydrolysis of its synthetic tetrapeptide substrate Suc-AAPL-pNA (7). rGzmM showed strong proteolytic activity even at low nanomolar concentration, whereas the mutant form S-AGzmM had no activity (data not shown).
A recent report showed GzmM induces a novel form of cell death that depends on perforin (21) . Perforin can assist all the Gzms into target cells to trigger death by a variety of assays (6, 23, 24) . Perforin transfers Gzms into the target cells through endocytosis and causes release of Gzms into the cytosol of target cells (4) . However, in vitro GzmB-loading experiments showed GzmB enters a target cell and induces apoptosis independently of perforin (25, 26) . Bleackley and colleagues (25, 27) demonstrated that a replication-deficient adenovirus type V (Ad) can efficiently transport GzmB into target cells and trigger cytolysis. We wanted to determine whether PJ can substitute for perforin or Ad to directly deliver Gzms into the target cell cytosol and induce cell death. PJ is used to deliver biologically active proteins directly into a living cell. Proteins loaded by PJ remain biologically active because the interaction between a protein and PJ is noncovalent. We loaded GzmM into Jurkat cells in the presence of an optimal dose of PJ and observed the entry of GzmM. GzmM transferred into the cytosol and the nuclei of treated cells within 4 h (Fig. 1A) . The nuclei appeared condensed, shrunken, and with morphological changes.
By 6 h, the nuclei treated by GzmM with PJ occurred segmented and collapsed. PJ and GzmM alone failed to make any change as mock-treated cells. Hoechst DNA staining obtained the similar apoptotic nuclear morphology in GzmM-and PJ-loaded cells (Fig.  1B) . PJ or GzmM alone was without effect. Apoptosis-inducing agent STP-treated cells appeared characteristic apoptosis as a positive control. Similar results were obtained by using Ad for GzmM loading (data not shown).
GzmM induces a caspase-dependent death pathway
Kelly et al. (21) (Fig. 2A) . GzmM and PJ alone or S-AGzmM and PJ just got background lysis (generally Ͻ10%). Similar results were found by using HeLa cells (data not shown). Jurkat cells loaded with different concentrations of GzmM plus PJ led to dynamic increase of cell death, as shown in Fig. 2B To determine whether GzmM/PJ-induced death is dependent on caspase activation, cells were preincubated with the pan caspase inhibitor ZVAD-fmk before GzmM loading. A total of 100 M ZVAD-fmk blocked GzmM/PJ-induced specific lysis measured by a standard 4-h 51 Cr release assay (14 Ϯ 2 vs 74 Ϯ 8%) ( Fig. 2A ) and annexin V/PI staining (data not shown). These data are representative of at least three separate experiments.
To further verify GzmM-induced death is caspase dependent, we analyzed caspase 3 cleavage by immunoblotting. Caspase activation is a key regulator of the apoptotic pathway for multiple inducers of cell death (28) . Procaspases are processed at aspartic acid residues between the subunits of a heterotetramer and can be activated by other caspases or by GzmB (29, 30) . Caspase 3 is a central executioner in the induction of apoptosis. Caspase 3 can be activated by processing its proenzyme procaspase 3 undergoing apoptosis. We found procaspase 3 was processed in GzmM-treated cell lysates with a dose-and time-dependent fashion (Fig. 3A) . Caspase 3 began to be processed with a low dose of 10 nM GzmM at very early time of 5 min. The active form p17 band was detectable at high dose of 1 M GzmM, which was comparable to 0.3 M GzmB treatment. The cleavage patterns by GzmM and B are different. Inactive S-AGzmM was without effect. To verify the caspase activation is physiologically relevant, Jurkat cells were loaded with GzmM in the presence of PJ. Procaspase 3 was cleaved to produce the active form, a p17 product in GzmM/PJloaded cells (Fig. 3B) . PJ or GzmM alone or S-AGzmM/PJ failed to cut procaspase 3. ␤-Actin was unchanged as a loading control. Taken together, GzmM-induced death is required for caspase activation.
GzmM fails to nick DNA
DNA damage is another feature of cell death. GzmA induces caspase-independent death with ssDNA nicking (6, 9) . DNA nicking is supposed to be an early stage of cell death induced by cytolytic lymphocytes. GzmM initiates a faster death pathway of target cells consistent with Kelly's report (21) . We next wanted to look at whether GzmM initiates ssDNA nicking. The Klenow polymerase labeling was used to assess DNA strand breaks, as described (12) . DNA nicks were not induced from GzmM-treated Jurkat nuclei, even with 1 M GzmM (Fig. 4A) , whereas extensive DNA nicking occurred with 0.5 M GzmA treatment under the same condition, which is in concert with our previous reports (12) . PJ-or S-AGzmM-treated nuclei were not nicked. These results were confirmed via denaturing alkaline gel electrophoresis, as shown in Fig. 4B . These data are representative of three separate experiments.
GzmM triggers DNA fragmentation
To determine the form of DNA damage in GzmM-induced death, genomic DNA was extracted from GzmM-treated nuclei. Characteristic apoptotic DNA ladders were visualized on agarose gels in GzmM-treated nuclei (Fig. 5A) . DNA laddering occurred in a dose-dependent manner. Mock-or S-AGzmM-treated nuclei were without effect. To further assess the DNA fragmentation induced by GzmM is physiologically relevant, GzmM was loaded into Jurkat cells in the presence of PJ. Genomic DNA was extracted and assayed to visualize DNA fragmentation from GzmM-loaded cells. DNA ladders appeared in GzmM/PJ-treated cells (Fig. 4B) . GzmM and PJ alone or S-AGzmM/PJ failed to damage DNA. A total of 100 M ZVAD-fmk nearly blocked GzmM-induced DNA laddering that is consistent with the above observations. To further confirm DNA damage induced by GzmM, fluorescein-dUTP-labeled TUNEL was used to detect the free 3Ј-OH DNA ends at a single cell level by fluorescence microscopy. GzmM/PJ-treated cells appeared TUNEL positive with strong staining (Fig. 5C) . PJ or GzmM alone was TUNEL negative.
GzmM directly cleaves the ICAD
CAD, also known as DFF40, has been verified to be directly responsible for DNA fragmentation. CAD exists as a heterodimer with its inhibitor ICAD (also called DFF45) that serves as both a specific molecular chaperone to mediate the correct folding of DFF40 and an inhibitor of the nuclease activity of DFF40 in resting cells (31) (32) (33) . CAD can be activated by cleavage of its inhibitor ICAD to initiate DNA fragmentation after a cell receives a death signal. To further determine whether ICAD is degraded by GzmM treatment, ICAD was probed by immunoblotting with anti-ICAD Ab. ICAD was cleaved to generate a predominant 30-kDa fragment in GzmM-treated cell lysates in a dose-dependent manner (Fig. 6A ). S-AGzmM had no proteolytic activity. ICAD began to degrade within 30 min and was almost completely processed by 2 h with 0.5 M GzmM treatment. S-AGzmM did not cause ICAD degradation. To investigate whether ICAD degradation occurs in GzmM-loaded cells, ICAD was probed in Jurkat cells loaded with GzmM plus PJ. ICAD was cleaved in GzmM/PJ-loaded cells (Fig.  6B) . GzmM or PJ alone or S-AGzmM plus PJ failed to degrade ICAD. The same blot was stripped and reprobed for ␤-actin. ␤-Actin was unchanged as a good loading control.
To further evaluate whether ICAD can be directly processed by GzmM, human rICAD was treated with different concentrations of GzmM. GzmM can directly cut rICAD to produce 11-and 30-kDa fragments beginning at low nanomolar concentrations (Fig. 6C) . rICAD was completely degraded with 50 nM GzmM. rICAD cleavage occurred very rapidly within 5 min at 100 nM concentration of GzmM. rICAD was completely degraded by 15 min. S-AGzmM did not lead to rICAD degradation. Caspase 3 was used as a positive control. We performed N-terminal sequencing of the cleaved products and showed the cleavage site was after Ser 107 (TAWIS2QESFD). This is different from GzmB.
PARP is degraded by GzmM
In cells, a NAD ϩ -dependent signal transduction mechanism serves to protect cells against the genome-destabilizing effects after DNA breaks. The mechanism involves two nuclear enzymes, PARP-1 and PARP-2, that sense DNA strand breaks. When activated by DNA breaks, these PARPs catalyze the transfer of ADP-ribose moiety from NAD ϩ to nuclear target substrates. Through recruitment of specific proteins at the site of damage and regulation of their activities, these polymers may either directly participate in the DNA repair process or coordinate repair through chromatin unfolding, cell cycle progression, and cell death (34, 35) . PARP is a sensor of DNA damage, which is a downstream substrate of caspase 3 and can be directly degraded by GzmB (36, 37) . We wanted to determine whether PARP is degraded after GzmM treatment. Human rPARP was incubated with different doses of GzmM at 37°C for 2 h. PARP was cleaved beginning at a low concentration of 30 nM GzmM (Fig. 7A) . A total of 50 nM GzmM can completely degrade PARP. PARP cleavage appeared rapidly within 15 min by 50 nM GzmM treatment. To further investigate whether PARP is a physiological substrate of GzmM, Jurkat cells were loaded with GzmM plus PJ and probed by immunoblotting with anti-PARP serum. PARP was completely cleaved to generate a 45-kDa product in GzmM-loaded cells within 4 h (Fig. 6B) . GzmM and PJ alone or S-AGzmM/PJ was without effect. Therefore, PARP is a direct physiological substrate of GzmM.
Discussion
Perforin was originally thought to generate pores in the target cell plasma membrane through which Gzms would get into cytosol (38, 39) . However, this model for Gzm entry has been questioned. At low concentrations, perforin delivers Gzms to trigger apoptosis, and at high concentrations perforin induces necrotic death. Actually, at a sublytic concentration the plasma membrane integrity is not disrupted; small dyes do not enter the cell (40, 41) . Froelich et al. (25) (26) (27) showed that a replication-deficient Ad can efficiently transport GzmB into targets and lead to apoptosis. Recent reports verified Gzms are taken into cells by endocytosis and perforin or Ad causes release of Gzms into the cytosol (4, 42) . Transient expression of GzmB or direct transfer of GzmB by microinjection can initiate cell death (27, 43) . It indicates that GzmB exerts its proapoptotic function inside a target cell independently of perforin. In this study, we showed a cationic lipid-based PJ can efficiently transport GzmM into target cells and induce cell death. PJ binds to proteins without covalent formation that moves proteins into cells, where proteins remain their physiological activities. GzmM alone did not enter the target cells. GzmM entry needs assistance of PJ or Ad that is consistent with perforin-dependent entry of GzmM (21) . Actually, an optimal dose of PJ was used to load GzmA or B into target cells, which led to similar apoptotic features as perforinor Ad-delivered GzmA or B (data not shown).
A recent study showed that GzmM causes a third major death pathway besides GzmA and B (21) . GzmM-induced death is independent of caspase activation and mitochondrial damage. GzmM does not trigger chromosomal DNA fragmentation by analyzing DNA content via PI staining. However, we found that GzmM initiates a caspase-dependent death pathway. The pan caspase inhibitor ZVAD (100 M) can completely block GzmMinduced cytolysis, DNA fragmentation, and procaspase 3 processing. Our observations are different from those of Kelly et al. (21) . They showed that even high concentration of 200 M ZVAD failed to inhibit GzmM-induced death. GzmM-treated cells did not cause caspase activation and phosphatidylserine externalization. We found GzmM initiated high rate of single annexin V ϩ cells and caspase activation. Although we used the different concentrations of GzmM and different delivery agents, we obtained the similar death rates by GzmM (1 M)/PJ and GzmM (83 nM)/perforin treatment. It indicates that the 1 M concentration of GzmM we used is equal in activity to 83 nM concentration used by Smyth group. Different GzmM activity might be due to the different expression systems. We produced GzmM in P. pastoris yeast, whereas Smyth group generated GzmM from baculovirus sf21 cells. The same death rates induced by GzmM (1 M)/PJ and GzmM (83 nM)/perforin might be also attributable to the delivery efficiency of the two different delivery agents. Caspases are central regulators of apoptotic pathway for multiple inducers of cell death (13) . Caspases are synthesized as a single polypeptide, act as a heterotetramer consisting of two large and two small subunits, and can be initiated by other caspases or GzmB (29, 30) . Although a number of caspases are processed by GzmB, caspases 3 and 7 are cleaved most rapidly in cells loaded GzmB with perforin (44, 45) . Caspase 3 is a central execution member of the caspase family.
DNA damage is a key feature of cell death. We previously showed GzmA triggers cell death with ssDNA nicks by targeting an endoplasmic reticulum-associated SET complex (6, 9) . The SET complex contains the GzmA-activated DNase NM23H1 that binds to its inhibitor SET in a resting cell. Cleavage of SET by GzmA unleashes the nuclease activity of NM23H1 to nick DNA (12) . DNA nicking is thought to be an initial stage of death induced through cytotoxic lymphocytes, followed by DNA fragmentation by other Gzms. In addition to GzmA, GzmC and K have been reported to cause DNA nicks (23, 46) . Only GzmB has been defined to make DNA fragmentation (3). We found GzmM did not cause DNA nicking, but led to typical DNA laddering. The DNA fragmentation induced by GzmM was verified by TUNEL assay. To further gain insight into the mechanism, we demonstrated that ICAD/DFF45 can be directly cleaved by GzmM. CAD/DFF40 has been defined to be directly responsible for DNA fragmentation. CAD remains in an inactive form with its inhibitor ICAD of normal cells (31) (32) (33) . Once a cell receives a death signal, caspase 3 is activated and it in turn cleaves ICAD, which activates the nuclease activity of CAD. ICAD acts as both an inhibitor of CAD and a specific nuclear chaperone to assist the correct folding of CAD. ICAD-deficient mice have a reduced ability to make DNA fragmentation, which is partially resistant to in vitro and in vivo induced apoptosis (16) . These indicate that CAD/ICAD complex plays an essential role in DNA fragmentation undergoing apoptosis. ICAD degradation by GzmB releases the nuclease activity of CAD to result in DNA fragmentation (14, 15) . GzmM also directly degrades ICAD to activate CAD activity. ICAD was cleaved to generate 11-and 30-kDa fragments, which were from one cut after Ser 107 (TAWIS2QESFD). The cleavage pattern by GzmM is different from that of GzmB, producing 28-and 31-kDa fragments at residues of D117 and D224. It has been reported GzmM prefers to cleave after methionine, leucine, or norleucine by measuring of synthetic peptides (18) . The cleavage sites of GzmM for physiological substrates remain to be further investigated.
PARP is a sensor enzyme of DNA damage. It has three functional domains, an N-terminal DNA binding domain, a C-terminal catalytic domain, and an automodification domain in the middle (lanes 7-12) . Untreated or 1.0 M S-AGzmM-treated sample served as a negative control. The products were electrophoresed on SDS gels and probed by anti-ICAD Ab. B, 2 ϫ 10 5 Jurkat cells were treated with 1.0 M GzmM, S-AGzmM alone, or PJ at 37°C for 4 h. The whole cell lysates were immunoblotted with anti-ICAD serum. ␤-Actin was unchanged as a negative control. C, rICAD (0.5 g) was treated with different doses of GzmM ranging from 5 to 100 nM (lanes 1-7) and 300 nM recombinant active caspase 3 for 2 h (lane 8). A total of 0.5 g of rICAD was incubated with 100 nM GzmM for the indicated times (lanes 9 -12) . The reaction products were probed, as described above.
part. Once DNA breaks, PARP is activated to bind to the DNA strand interruptions through its DNA binding domain. Activated PARP catalyzes formation of long and branched polymers of ADP-ribose using NAD as a substrate (47) . These polymers recruit specific proteins at the DNA damage site and enhance their activities to participate in DNA repair or coordinate repair via regulation of other cellular DNA-related functions (34, 35) . PARP is specifically activated at a very early stage of apoptosis, while the cell continues to retain membrane integrity and the majority of the proteins are not cleaved (48) . PARP is directly processed to produce a 89-kDa product by caspase 3-like activity undergoing apoptosis (37), whereas PARP is cleaved to generate 89-and 64-kDa fragments in GzmB-mediated cytolysis. The dual pattern for cleavage of PARP by GzmB indicates GzmB not only activates caspases, but also enters the nucleus to directly degrade PARP. GzmM can directly cleave PARP to produce a 45-kDa fragment, which is different from that generated by caspase 3-like activity or GzmB.
Unlike GzmB, GzmM is not expressed in CD4 ϩ or CD8 ϩ T cells either constitutively or after activation (19) . However, GzmM is constitutively highly expressed in NK cells as is perforin. A recent report showed a human NK cell line KHYG-1 appears to have greater killing activity that is consistent with higher GzmM expression (20) , although GzmA and B are undetectable. It suggests that GzmM may play a crucial role in NK cell-mediated cytolysis. In fact, reports by us and Kelly et al. (21) demonstrated that GzmM-induced rapid cell death is in concert with the kinetics of cytolysis by NK cells. But we found that GzmM-induced cell death is dependent on caspase activation and DNA fragmentation reminiscent of GzmB. NK cells are the effectors of the innate immunity, acting as the first line of defense against viral infection and tumors (49) . A recent report from NK cell depletion experiments showed NK cells are critical for tumor immunity (50) . They exert their effector function without prior sensitization. Manipulating NK cells to eradicate tumors may be a powerful approach for cancer immunotherapy. Therefore, to fully understand the biology and function of NK cells will provide the basis for their potential clinical applications.
